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Decreased excretion of nitrate and nitrite in essential hyperten-
sives with renal vasoconstriction. Most hypertensive patients
exhibit increased renal vascular resistance (RVR). This study was
designed to investigate whether there exists any relationship
between RVR and the production of nitric oxide (NO) in patients
with essential hypertension. The study was performed in 49
non-treated patients with mild-to-moderate essential hyperten-
sion, and 20 age- and sex-matched normotensive subjects on a
controlled sodium diet. Renal hemodynamics was measured in
terms of the clearance of para-aminohippuric acid and inulin.
Urinary excretion of nitrate and nitrite (NO3
2 plus NO2
2) was
determined as an index of NO production. As compared with
normotensives, hypertensive patients exhibited higher (P , 0.001)
RVR and lower (P , 0.05) urinary excretion of NO3
2 plus NO2
2.
With the 100% confidence (upper) limit of the normotensive
population as a cut-off point, a subgroup of 30 hypertensives had
an abnormally high RVR. The excretion of NO3
2 plus NO2
2 was
lower (P , 0.005) in hypertensives with high RVR than in
normotensives and the remaining hypertensives. No differences
were found in the urinary excretion of NO3
2 plus NO2
2 between
normotensives and hypertensives with normal RVR. Statistically
significant associations were seen between diastolic blood pres-
sure and RVR (r 5 0.341, P , 0.05) and urinary excretion of
NO3
2 plus NO2
2 (r 5 20.387, P , 0.01) in all hypertensives.
These results indicate that there is a subgroup (61%) of hyper-
tensive patients with diminished urine levels of NO3
2 plus NO2
2
in which RVR is abnormally increased. Thus, it is suggested that
in essential hypertension a diminished renal ability to produce NO
by the endothelium may be involved in exaggerated renal vaso-
constriction.
It is well known that most patients with established
essential hypertension exhibit increased renal vascular re-
sistance (RVR) [reviewed in 1]. The mechanism(s) under-
lying the appearance of renal vasoconstriction in arterial
hypertension remains to be clarified. It has been attributed
to an abnormal renal response to prevailing intrarenal
levels of angiotensin II [2] and increased renal sympathetic
activity [3]. An alternative explanation of how the increase
of RVR develops in hypertension is through a defect in the
synthesis of a humoral factor that mediates renal vasodila-
tion. For instance, it has been shown that nitric oxide (NO)
modulates angiotensin II- and norepinephrine-dependent
renal vasoconstriction [4]. In addition, a number of exper-
imental [5, 6] and clinical [7, 8] findings suggest that a
diminution in the availability of NO could be involved in
renal vasoconstriction seen in primary hypertension.
We therefore hypothesized that a diminished production
of NO by the endothelium might be involved in the increase
in RVR in arterial hypertension. To test this hypothesis we
analyzed the relationships between renal hemodynamics
and the urinary excretion of nitrate plus nitrite (NO3
2 plus
NO2
2), an index of NO production, in patients with
essential hypertension separated into two groups: those
with abnormally high RVR and those with normal RVR.
METHODS
The study design was reviewed and approved by the
Institutional review boards of the San Milla´n Hospital. The
hypertensive group consisted of 49 never-treated Caucasian
hypertensive patients. All had been classified as having
stage 1 or 2 hypertension [9]. Causes of secondary hyper-
tension were excluded after a complete medical work-up.
The control group consisted of 20 age- and sex-matched
Caucasian normotensive subjects. Throughout the study, all
the subjects ingested the same basic diet containing 10 g
NaCl (170 mmol sodium)/day.
Glomerular filtration rate (GFR) and effective renal
plasma flow (ERPF) were then measured by inulin and
para-aminohippurate (PAH) clearances. Inulin was mea-
sured in plasma and urine by an enzymatic method. PAH
was determined in plasma and urine by a fluorometric
method. The clearance rates of inulin and PAH were
calculated from the standard equation and corrected to a
body surface area of 1.73 m2. The renal blood flow (RBF)
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was calculated from ERPF and hematocrit. The mean
arterial pressure (MAP) was divided by RBF for estimation
of renal vascular resistance (RVR). Filtration fraction (FF)
was calculated by the equation GFR/ERPF 3 100.
The method to determine NO3
2 plus NO2
2 in urine
consisted in a two-step process: the first step was the
conversion of NO3
2 to NO2
2 utilizing nitrate reductase;
the second step was the addition of the Griess reagent,
which is a mixture of sulfanilic acid and N-(1-naphthyl)
ethylenediamine [10]. N-(1-naphthyl) ethylenediamine re-
acts with NO2
2 to form a purple azo dye. Absorbance was
detected at 540 nm using a flow-through visible spectro-
photometer.
Values are expressed as mean 6 SEM. The differences
between normotensives and the whole group of hyperten-
sives were compared with unpaired Student’s t-tests. A
Scheffe´’s two-way ANOVA test was used to compare
baseline values between normotensives, hypertensives with
normal RVR and hypertensives with high RVR. The
correlation between continuously distributed variables was
tested by univariate regression analysis.
RESULTS
The RVR in normotensives ranged from 3099 to 9261
dyns z sec z cm25 (mean, 6837 6 407 dyns z sec z cm25). No
significant differences in RVR were observed between
males and females (data not shown). In addition, the values
of RVR were not influenced by either age or body surface
(data not shown). The RVR was increased (P , 0.001) in
the whole group of hypertensives as compared with the
group of normotensives (mean 10752 6 547 dyns z sec z
cm25; range, 5053 to 22468).
Figure 1 shows individual values of RVR in hyperten-
sives. If the upper end of the normotensive population is
used as a cut-off point, it appears that a subgroup of 30
hypertensives had an increased RVR (mean 12900 6 617
dyns z sec z cm25; range, 9583 to 22468). Thus, we consid-
ered these patients as hypertensive with high RVR (sub-
group H). The values of RVR were within the normal
range in the remaining 19 patients (mean 7360 6 226 dyns
z sec z cm25; range, 5053 to 9117). Thus, we considered
these patients as hypertensive with normal RVR (subgroup
N). The RVR was increased (P , 0.001) in hypertensives
from subgroup H as compared with hypertensives from
subgroup N and normotensives.
The RBF was lower (P , 0.001) in hypertensives from
subgroup H (697 6 25 ml/min/1.73 m2) than in normoten-
sives (950 6 62 ml/min/1.73 m2) and hypertensives from
subgroup N (1123 6 42 ml/min/1.73 m2). The GFR was
lower (P , 0.05) in hypertensives from subgroup H (98 6
4 ml/min/1.73 m2) than in hypertensives from subgroup N
(116 6 6 ml/min/1.73 m2). No differences were found in
this parameter between hypertensives from subgroup H
and normotensives (105 6 5 ml/min/1.73 m2). The FF was
increased (P , 0.005) in hypertensives from subgroup H
(26 6 1%) as compared with hypertensives from subgroup
N (19 6 1%) and normotensives (20 6 1%). No differences
were found in this parameter between hypertensives from
subgroup N and normotensives.
As expected, systolic and diastolic blood pressure levels
were increased (P , 0.001) in the two subgroups of
hypertensives compared with normotensives (data not
shown). The values of mean arterial pressure were higher
(P , 0.05) in hypertensives from subgroup H (122 6 2 mm
Hg) than in hypertensives from subgroup N (112 6 2 mm
Hg). Although the duration time of hypertensive disease
was lesser in hypertensives from subgroup H (28 6 7
months) than in hypertensives from subgroup N (41 6 12
months), the difference did not reach statistical signifi-
cance. The general demographic parameters (gender, age
and body mass index) in the 30 hypertensives from sub-
group H were not significantly different from those of the
other 19 hypertensives (data not shown).
The excretion of NO3
2 plus NO2
2 was lower (P , 0.05)
in the whole group of hypertensives than in the group of
normotensives (770 6 102 vs. 1216 6 150 mmol/day). The
excretion of NO3
2 plus NO2
2 was lower (P , 0.005) in
hypertensives from subgroup H (428 6 72 mmol/day) than
in hypertensives from subgroup N (897 6 132 mmol/day)
and normotensives (Fig. 2). No significant differences were
found in the excretion of NO3
2 plus NO2
2 between
hypertensives from subgroup N and normotensives (Fig. 2).
A statistically significant association was seen between
RVR and the following parameters in all hypertensives:
diastolic blood pressure (y 5 24457 1 154x, r 5 0.341, P ,
0.05); mean arterial pressure (y 5 21930 1 110x, r 5 0.282,
P , 0.05); RBF (y 5 21863 to 13x, r 5 20.880, P , 0.001),
GFR (y 5 17672 to 65x, r 5 20.445, P , 0.01) and FF (y 5
2264 1 369x, r 5 0.678, P , 0.001). The excretion of NO3
2
Fig. 1. Data points show the values of the renal vascular resistance
(RVR) in normotensive subjects (Controls), hypertensive patients with
normal RVR (Subgroup N) and hypertensive patients with high RVR
(Subgroup H).
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plus NO2
2 was inversely correlated with diastolic blood
pressure (y 5 3964 to 32x, r 5 20.387, P , 0.01) in all
hypertensives. No other significant correlations were found
between urinary NO3
2 plus NO2
2 and other parameters
measured in this study.
DISCUSSION
This study confirms previous clinical data showing that
RVR is significantly higher in patients with arterial hyper-
tension than in normotensive individuals [1]. More specif-
ically, we found that compared with values obtained in
normotensives, an abnormally high level of RVR was
present in 30 hypertensives (61%). Therefore, the above 30
hypertensives were considered hypertensive with exagger-
ated renal vasoconstriction (subgroup H). The remaining
19 hypertensives (39%) did not exhibit this alteration in
RVR. Thus, we have termed these patients as hypertensive
with normal renal vasoconstriction (subgroup N). Hyper-
tensives from subgroup H exhibit the classical abnormali-
ties of renal hemodynamics found in patients with non-
severe forms of essential hypertension [11]: reduced RBF,
tendency to subnormal GFR and raised FF because of the
proportionally greater impairment of RBF than of GFR.
It has been demonstrated that the elevation in renal
arterial perfusion pressure (RPP) results in an increase in
RVR [12] due to the autonomic contraction of the vascular
smooth muscle cells triggered by the stretch of arterial walls
during increments of RPP [13]. Since the mean arterial
pressure was higher in hypertensive patients from subgroup
H than in hypertensive patients from subgroup N, and a
direct correlation was found between mean arterial pres-
sure and RVR in all hypertensives, it is tempting to
speculate that the exaggerated renal vasoconstriction seen
in hypertensive patients from subgroup H reflects an
exaggerated autoregulatory response to the elevated sys-
temic arterial pressure. However, two kinds of findings
suggest that a humoral factor may be also involved in the
abnormal response of renal vasculature to the increase in
systemic pressure. First, it has been reported that increased
renal vasoconstriction is already present in normotensive
offspring of hypertensive parents [14–16]. Second, renal
vasoconstriction in SHR is reversed by treatment with an
angiotensin converting enzyme inhibitor [17], but not by
treatment with hydrochlorothiazide [18], despite a similar
decrease of blood pressure caused by both types of agents.
As shown by Imig and Roman [19], during the elevation
of RPP, the decrease in arterial diameter results in an
elevation of blood flow velocity and thereby a proportional
increase in shear stress stimulating the release of NO in the
distal portion of pre-glomerular circulation. It, thus, has
been proposed that one of the main physiological functions
of NO could be to modulate myogenic contractile response
of autoregulation, preventing an excessive fall in RBF and
GFR [20]. This is supported by the studies of Salom et al
[21], who found that inhibition of NO by the intravenous
infusion Nv-nitro-L-arginine methyl ester (L-NAME) in a
group of euvolemic rats whose kidneys were being perfused
at 150 mm Hg was followed by a 30% reduction in RBF. In
contrast, no effects were seen in RBF when L-NAME was
given to rats whose RPP was 110 mm Hg. We therefore
decided to measure the baseline production of NO in the
hypertensive patients of the current study.
The final products of NO in vivo are NO3
2 and nitrite
NO2
2. The relative proportion of the two compounds
cannot be predicted with certainty. Thus, the best index of
total NO production is the sum of both NO3
2 plus NO2
2.
Sawada et al [22] reported that the serum levels of NO3
2
plus NO2
2 in rats increased markedly immediately after an
intravenous injection of acetylcholine. In addition, the
same group reported recently that oral administration of
L-NAME reduced serum levels and urinary excretion of
NO3
2 plus NO2
2 to approximately 50 and 25%, respec-
tively, of the levels in control rats [23]. On the other hand,
the determination of NO3
2 plus NO2
2 allows a differenti-
ation between changes in NO production and changes in
NO inactivation, because urinary NO3
2 indicates the en-
dogenous formation of NO irrespectively of whether this
NO was biologically active or whether it had been inacti-
vated early (NO oxidatively inactivated by O2
2 is also
converted in the final metabolite, NO3
2) [24].
Therefore, our finding that the urinary excretion of
NO3
2 plus NO2
2 was abnormally diminished in hyperten-
sives would suggest that the total (that is, renal and
extrarenal) production of NO is depressed in these pa-
tients. In accordance with this, we propose that a dimin-
ished ability of the renal vasculature to produce NO can be
involved in the increased renal vasocontriction present in
Fig. 2. Values of the urinary excretion of nitrate and nitrite (NO32 plus
NO22) measured in each group of subjects. The bars represent the
mean 6 SEM in each group. A Scheffe´’s two-way ANOVA test was applied
to assess the statistical significance of differences among groups. [Con-
trols, normotensive subjects; Subgroup N, hypertensive patients with
normal renal vascular resistance (RVR); Subgroup H, hypertensive pa-
tients with high RVR] (*P , 0.005 as compared to normotensives and
hypertensives from Subgroup N).
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hypertensive patients from subgroup H. Several arguments
support this possibility. First, it has been recently reported
that inhibition of NO in healthy humans is accompanied by
strong renal vasoconstriction [25]. Second, the existence of
a blunted renal vasodilation has been reported in response
to L-arginine in essential hypertensive patients as com-
pared to normotensives [7, 8]. Third, it has been shown that
a diminished availability of NO can be involved in the
exaggerated renal vasoconstriction observed in SHR [5, 6].
In summary, the data of the current study show an
increased resistance in the renal vasculature in two thirds of
patients with essential hypertension. Hypertensive patients
with an abnormally high RVR may represent a particular
subset of essential hypertensives characterized by dimin-
ished production of NO. Endothelial dysfunction of the
renal vessels may, therefore, be involved in the compro-
mised renal hemodynamics of essential hypertensives. This
association can be of interest when considering the reno-
protective effects of antihypertensive treatment in hyper-
tensive patients.
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